Bifogade filer
Kurs & Likviditet
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Newbury Pharmaceuticals via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
2024-09-13 11:30:00
Newbury has through one of its partners initiated a DCP filing for Teduglutide on Day-1 following the expiry of Data Exclusivity.
Teduglutide has been developed for the treatment of short bowel syndrome (SBS), a rare condition that impairs the small intestine’s ability to properly absorb nutrients and fluids.
This submission presents a first-to-market opportunity for Newbury, emphasizing our commitment to addressing unmet medical needs in the rare disease segment. Launch is anticipated to take place in 2026.
Teduglutide achieved a turnover of approximately 10 M€ in the Nordics during the past 12 months, according to DLMI (MAT August 2024).